RecruitingNot ApplicableNCT06720922
MRgLITT for mTLE: A PROBE Trial
Magnetic Resonance-guided Laser Interstitial Thermal Therapy for Mesial Temporal Lobe Epilepsy: A Prospective, Randomized, Open Blinded, End-point Trial
Sponsor
Beijing Tiantan Hospital
Enrollment
120 participants
Start Date
Jul 21, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
How does magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) impact clinical prognosis in mesial temporal lobe epilepsy (mTLE)?
Eligibility
Inclusion Criteria4
- -65 years.
- Drug-resistant mesial temporal lobe epilepsy.
- Seizure frequency ≥ 1 time /month.
- Participants approved.
Exclusion Criteria3
- History of brain surgery.
- Intracranial space occupying lesions.
- Individuals with significant medical comorbidities or conditions that pose an excessive risk for surgery, such as severe cardiovascular disease, respiratory disorders, or uncontrolled systemic infections.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
PROCEDUREResonance-guided Laser Interstitial Thermal Therapy (MRgLITT)
MRgLITT employs laser energy delivered through a stereotactically placed laser applicator to precisely ablate the epileptogenic tissue.
PROCEDUREOpen Surgery
Traditional Open Surgery
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06720922